Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Leaderboard Analytics
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
Veljanoski v. Juno Therapeutics, Inc. et al
Case Number:
2:16-cv-01069
Court:
Nature of Suit:
Multi Party Litigation:
Class Action
Judge:
Firms
- Badgley Mullins
- Block & Leviton
- Cravath Swaine
- McNaul Ebel
- Pomerantz LLP
- Tousley Brain
- Wilson Sonsini
Companies
Sectors & Industries:
-
August 03, 2018
Juno Investors Reach $24M Deal In Stock-Drop Class Action
A certified class of investors in Juno Therapeutics told a Washington federal judge on Thursday that it has reached a $24 million settlement to resolve claims that the biopharmaceutical company's failure to disclose the death of one of its immunotherapy patients led to a 30 percent drop in its share price.
-
October 24, 2017
Pomerantz Gets Lead Role As Juno Investor Class Certified
Investors claiming the immunotherapy company Juno Therapeutics failed to inform them of the health risks associated with one of its drugs received class certification on Tuesday in Washington federal court, and Pomerantz LLP was appointed lead class counsel.